Please assess the completion status of the following clinical trial:

Trial Title: Drug Treatment for Alcoholics With Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the criteria for alcohol dependence with comorbid bipolar disorder.~* Agreement to participate in outpatient treatment.~* Ability to tolerate lithium carbonate and be randomized to receive sodium valproate or placebo.~* Stable living situation.~* Ability to provide informed consent.~Exclusion Criteria:~* Psychiatric conditions including schizophrenia, schizoaffective disorder, any non-bipolar psychotic disorder, unipolar major depression, mental retardation, or signs of impaired cognitive functioning.~* Neurological conditions including epilepsy, history of brain injury, encephalitis, or any organic brain syndrome or focally abnormal electroencephalographic examination.~* Medical conditions including severe cardiac, liver, kidney, endocrine, hematologic, other impairing or unstable medical condition or impending surgery.~* Persistent elevation of liver function enzymes indicating active liver disease.~* Pregnancy or not using an acceptable contraceptive method.~* Inability to read or understand study forms; agree to informed consent.~* Impending incarceration or a mandate to attend treatment by the legal system for an alcohol use disorder.~* The presence of either/or cocaine dependence, opioid dependence, and intravenous drug use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- sodium valproate (Type: ACTIVE_COMPARATOR): sodium valproate was added on treatment as usual and dose monitored by blood level measurements
- placebo (Type: PLACEBO_COMPARATOR): Placebo comparator was added on treatment as usual and dose monitored by blood level measurements

Based on this trial design, predict the completion outcome and termination type (if applicable).